Through the partnership, HHS’ Biomedical Advanced Research and Development Authority will give Summit $32 million over two years to conduct two Phase 3 clinical trials of its experimental drug Ridinilazole.
The drugmaker is also eligible to receive a three-year extension on the contract with total potential funding of $62 million.
To learn more about C diff, click here.
More articles on infection control:
Study suggests possible link between repeat flu vaccination and miscarriage
Study: Antibiotic use may boost superbug spread in nursing homes
Pet store puppies sicken 39 people in multistate bacterial outbreak
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
